Search Results

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, announced the closing of its merger with Biosight, Ltd., pursuant to which Ayala acquired Biosight.

Ayala Pharmaceuticals, Inc. and Biosight Ltd. today announced they have entered into a definitive merger agreement pursuant to which Ayala will combine with Biosight in an all-stock transaction.

Biosight Ltd today announced enrollment of a first patient to a phase 1/2 clinical trial designed to evaluate the safety and efficacy of its lead asset aspacytarabine (BST-236) in combination with the BCL2 inhibitor venetoclax for induction therapy of newly-diagnosed Acute Myeloid Leukemia (AML), followed by aspacytarabine single-agent consolidation therapy.

Biosight Ltd., announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to aspacytarabine (BST-236), an investigational novel antimetabolite, for the treatment of myelodysplastic syndromes, in addition to the Orphan Drug Designation granted in 2019 for aspacytarabine for the treatment of acute myeloid leukemia (AML).